BRICANYL
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
Mar 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRICANYL is a metered-dose aerosol inhalation product approved in 1985 as a small-molecule bronchodilator. It is used to treat respiratory conditions where airway constriction is a concern. The drug works as a beta-2 agonist to relax bronchial smooth muscle and improve airflow.
LOE Approaching
As LOE approaches, the brand team is likely focused on lifecycle management and defending market share against generic competition in a moderately competitive landscape.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3
Started Mar 2015
95 enrolled
Asthma
Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients
Started Sep 2009
66 enrolled
Exercise Induced Asthma
Career Relevance
Working on BRICANYL as it approaches LOE offers experience in lifecycle defense, generic competition management, and market access strategy—valuable for career development in mature asset management. Roles are concentrated in commercial, compliance, and operations rather than discovery or expansion.
Worked on BRICANYL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.